Using a new type of PET scanner for imaging prostate cancer and related conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the clinical application of the J-PET scanner prototype, which utilizes plastic scintillators instead of traditional crystal scintillators for positron emission tomography (PET). The J-PET scanner aims to enhance the sensitivity and accuracy of imaging metabolic changes associated with prostate cancer and other prostatic conditions. Participants will undergo a PET/CT scan as part of their routine clinical care, and the study will assess the scanner's performance in detecting biochemical alterations at an early stage. The research is conducted at the Department of Experimental Particle Physics and Applications at Jagiellonian University in Krakow.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient is referred for a PET/CT scan, in accordance with recognized indications for examining the entire body.
* Age over 18 years
* Informed, voluntary consent to participate in the study

Exclusion Criteria:

* Pregnant women, breastfeeding women
* People with a previously diagnosed allergy to radiopharmaceuticals
* Age under 18 years
* Lack of cooperation with the patient
* Lack of informed consent to participate in the study

Where it's running

• Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow
  Krakow, Poland Recruiting

Study contacts

• Principal investigator: Marta Opalinska, MD, PhD — Department of Endocrinology and Nuclear Medicine, University Hospital in Krakow
• Study coordinator: Pawel Moskal, PhD
• Email: p.moskal@uj.edu.pl
• Phone: 800-555-5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• Treatment for advanced prostate cancer using Pluvicto

  This study is testing if a new treatment called Pluvicto can help men with advanced prostate cancer that has spread to their bones feel better and improve their quality of life.

  Recruiting Phase 2 Excel Diagnostics and Nuclear Oncology Center · Houston, Texas · NCT06972628

• New treatment for metastatic prostate cancer using ifinatamab deruxtecan

  This study is testing a new treatment called ifinatamab deruxtecan to see if it helps men with advanced prostate cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 290 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 302 other locations · NCT06925737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.